Table 1.
Characteristics of patients with drug-resistant chronic hepatitis B stratified by hepatocellular carcinoma status n (%)
| Variables | Patients with HCC (n = 57) | Patients without HCC (n = 375) | P-value |
| Gender (male) | 42 (73.7) | 267 (71.2) | 0.755 |
| Age (mean, yr) | 57.44 ± 8.35 | 47.03 ± 12.25 | < 0.001 |
| Presence of cirrhosis | 42 (73.7) | 85 (22.7) | < 0.001 |
| HBeAg positivity | 36 (63.2) | 314 (83.7) | 0.003 |
| Seroconversion of HBeAg | 3 (5.3) | 78 (20.8) | 0.022 |
| Initial HBV DNA (< 2000 IU) | 2 (3.5) | 27 (7.2) | 0.61 |
| Initial HBV DNA (> 20000 IU) | 46 (80.7) | 314 (83.7) | 0.162 |
| Complete virologic response | 11 (19.3) | 135 (36) | 0.02 |
| Partial virologic response | 31 (54.4) | 271 (72.3) | 0.012 |
| Platelet count (103/mm3) (median, range) | 103 (35-380) | 164.5 (34-330) | < 0.001 |
| AST U/L (median, range) | 79.5 (22-707) | 63 (14-1494) | 0.126 |
| ALT U/L (median, range) | 86.5 (11-590) | 82 (9-2280) | 0.770 |
| AFP IU/mL (median, range) | 7.58 (1.54-1890) | 2.8 (0.65-980) | < 0.001 |
| Child-Pugh score | 5.51 ± 0.85 | 5.12 ± 0.71 | 0.002 |
| Viral mutation | |||
| rtM204I | 25 (43.9) | 93 (24.8) | 0.004 |
| rtM204I/rtL180M | 4 (7) | 50 (13.3) | 0.098 |
| rtM204V/rtL180M | 14 (24.6) | 111 (29.6) | 0.492 |
| rtM204V + I/rtL180M | 3 (5.3) | 36 (9.6) | 0.451 |
| rtA181T | 3 (5.3) | 22 (5.9) | 1 |
| rtA181T/V | 1 (1.8) | 1 (0.26) | 0.224 |
| Duration of antiviral treatment (mo) | 24.31 ± 15.28 | 31.43 ± 19.43 | 0.004 |
HCC: Hepatocellular carcinoma; ALT: Alanine aminotransferase; AFP: Alpha-fetoprotein; AST: Aspartate aminotransferase; HBV: Hepatitis B virus.